Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2013 10:40 ET | Source: Repros Therapeutics Inc.

Repros to Present at Biocentury's NewsMakers in the Biotech Industry Conference

THE WOODLANDS, Texas, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski, President and CEO of Repros Therapeutics, will be...
September 18, 2013 10:27 ET | Source: Repros Therapeutics Inc.

Repros Provides Additional Information Confirming Success for Study ZA-302

SPA Co-Primary Endpoints Met Results In Line with Study ZA-301 Findings All Studies Fully Compliant with FDA Good Clinical Practice THE WOODLANDS, Texas, Sept. 18, 2013 (GLOBE NEWSWIRE) --...
September 16, 2013 20:01 ET | Source: Repros Therapeutics Inc.

Repros Reports Preliminary Findings: Second Pivotal Study and 6-Month Safety Study Support Androxal(R) Approvability

Androxal meets both co-primary endpoints in second pivotal study ZA-302 Testosterone normalized in 81% of patients No deleterious effects on sperm function No excursions...
August 20, 2013 16:01 ET | Source: Repros Therapeutics Inc.

Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303

No bone loss compared to placebo Early evidence of improving bone mineral density in Androxal® subjects THE WOODLANDS, Texas, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics...
August 07, 2013 09:01 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results

THE WOODLANDS, Texas, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2013. Liquidity and...
August 05, 2013 09:00 ET | Source: Repros Therapeutics Inc.

Repros Seeks to Affirm Its Intellectual Property Rights in Androxal(R)

THE WOODLANDS, Texas, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has filed an action in the United States District Court for the Southern District...
July 09, 2013 13:15 ET | Source: Repros Therapeutics Inc.

Repros Announces Formation of Androxal(R) Clinical and Commercial Advisory Board

THE WOODLANDS, Texas, July 9, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the formation of an international, multi-disciplinary, clinical advisory board to...
June 25, 2013 11:47 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Announces the Closing of Public Offering of Common Stock

THE WOODLANDS, Texas, June 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has closed an underwritten public offering of 4,312,500 shares of its common...
June 19, 2013 19:35 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Announces Pricing of Public Offering of Common Stock

THE WOODLANDS, Texas, June 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at...
June 17, 2013 16:01 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Announces Proposed Public Offering of Common Stock

THE WOODLANDS, Texas, June 17, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has commenced an underwritten public offering of up to 3,000,000 shares of its...